NYSE$LH
Laboratory Corp Of America Holdings · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Labcorp's Q3 2022 results were announced, showing a decrease in revenue and earnings compared to the previous year, while strategic progress was made with the clinical development business spin-off and the establishment of a long-term relationship with Ascension.
Labcorp reported a decrease in revenue for Q3 2022, with $3.61 billion compared to $4.06 billion in Q3 2021. Diluted EPS decreased to $3.90 from $6.05, and adjusted EPS decreased to $4.68 from $6.82. The company is progressing with the spin-off of its Clinical Development business and has completed transactions to establish a long-term relationship with Ascension.
- Revenue for Q3 2022 was $3.6 billion, a decrease of 11.2% compared to Q3 2021.
- Diluted EPS for Q3 2022 was $3.90, compared to $6.05 in Q3 2021.
- Adjusted EPS for Q3 2022 was $4.68, compared to $6.82 in Q3 2021.
- Free cash flow for Q3 2022 was $270 million, compared to $650 million in Q3 2021.
Headline financials
Revenue & EPS history
LabCorp · Revenue · Quarterly
$3.61B
Revenue by segment
LabCorp · $3.61B total across 2 segments · Q3 2022
- Diagnostics Laboratories$2.21B-15.7%61.1%
- Biopharma Laboratory Services$1.41B-3.7%38.9%
Forward guidance
Labcorp is updating 2022 full year guidance to reflect its third quarter performance and fourth quarter outlook. The following guidance assumes foreign exchange rates effective as of September 30, 2022, for the remainder of the year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.
Tailwinds
- Base Business Revenue Total Labcorp Enterprise to be between (6.0%) and (2.0%)
- Base Business Revenue to be between 3.0% and 4.0%
- COVID-19 Testing Revenue to be between (59.0%) and (57.0%)
- Base Business Total Diagnostics to be between 6.0% and 7.0%
- Adjusted EPS to be between $19.25 and $20.25
Headwinds
- Revenue Total Labcorp Enterprise to be between (7.5%) and (6.0%)
- COVID-19 Testing Revenue to be between (60.0%) and (50.0%)
- Total Diagnostics to be between (11.5%) and (10.0%)
- Total Drug Development to be between (2.5%) and (1.5%)
- Free Cash Flow to be between $1.3 and $1.4
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.3%
Avg return
Earnings day
-0.6%
Avg return
5 days after
-0.9%
Avg return
30 days after
48%
35 / 73 earnings
Positive
+9.5%
Q2 2024
Best reaction
-10.4%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.0% | +0.0% | +1.3% | |
| Q4 2025 | -2.1% | +0.0% | -6.6% | |
| Q3 2025 | -5.7% | -7.9% | -2.7% | |
| Q2 2025 | -0.5% | +1.2% | +2.0% | |
| Q1 2025 | +4.7% | +7.9% | +7.5% | |
| Q4 2024 | -0.9% | -1.9% | +1.2% | |
| Q3 2024 | +4.0% | +3.7% | +9.0% | |
| Q2 2024 | +9.5% | +4.8% | +6.7% | |
| Q1 2024 | -4.6% | -3.2% | -4.0% | |
| Q4 2023 | -5.0% | -5.5% | -8.3% | |
| Q3 2023 | +0.6% | +1.0% | +7.6% | |
| Q2 2023 | -1.9% | -2.4% | -3.0% | |
| Q1 2023 | -4.6% | -2.5% | -8.2% | |
| Q4 2022 | +3.2% | -0.4% | -14.1% | |
| Q3 2022 | -2.5% | -3.2% | +5.0% | |
| Q2 2022 | +5.1% | +1.2% | -8.1% | |
| Q1 2022 | -5.0% | -3.1% | +1.9% | |
| Q4 2021 | -1.9% | -6.0% | -5.7% | |
| Q3 2021 | +2.3% | +2.0% | +3.1% | |
| Q2 2021 | +4.6% | +6.0% | +6.1% | |
| Q1 2021 | +1.2% | +4.1% | +4.5% | |
| Q4 2020 | +4.0% | +3.1% | +4.1% | |
| Q3 2020 | +1.0% | -1.1% | -2.7% | |
| Q2 2020 | -3.3% | -4.2% | -13.4% | |
| Q1 2020 | -6.5% | -10.4% | -0.4% | |
| Q4 2019 | +4.1% | +1.8% | -19.5% | |
| Q3 2019 | -2.0% | -2.3% | +0.4% | |
| Q2 2019 | -6.5% | -4.2% | -6.9% | |
| Q1 2019 | +3.7% | +6.1% | +5.1% | |
| Q4 2018 | +2.5% | +3.8% | +3.7% | |
| Q3 2018 | -7.1% | -6.2% | -4.1% | |
| Q2 2018 | -5.4% | -6.4% | -5.3% | |
| Q1 2018 | +3.9% | +2.8% | +9.7% | |
| Q4 2017 | +3.9% | +3.0% | +5.9% | |
| Q3 2017 | +1.7% | +2.2% | +0.2% | |
| Q2 2017 | +2.0% | +1.3% | -1.4% | |
| Q1 2017 | -4.1% | -3.1% | -1.9% | |
| Q4 2016 | +2.4% | +2.4% | +5.4% | |
| Q3 2016 | -10.4% | -9.4% | -7.9% | |
| Q2 2016 | +0.4% | +1.2% | -1.4% | |
| Q1 2016 | +4.1% | — | — | |
| Q4 2015 | +2.8% | — | — | |
| Q3 2015 | +7.8% | — | — | |
| Q2 2015 | +3.8% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | +4.9% | — | — | |
| Q3 2014 | +3.5% | — | — | |
| Q2 2014 | -0.5% | — | — | |
| Q1 2014 | -0.7% | — | — | |
| Q4 2013 | +1.1% | — | — | |
| Q3 2013 | -3.2% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.7% | — | — | |
| Q4 2012 | -1.7% | — | — | |
| Q3 2012 | -4.0% | — | — | |
| Q2 2012 | -9.0% | — | — | |
| Q1 2012 | -3.4% | — | — | |
| Q4 2011 | +2.2% | — | — | |
| Q3 2011 | -6.6% | — | — | |
| Q2 2011 | -0.6% | — | — | |
| Q1 2011 | +1.4% | — | — | |
| Q4 2010 | -0.2% | — | — | |
| Q4 2007 | -0.2% | — | — | |
| Q3 2010 | +1.6% | — | — | |
| Q2 2010 | +0.9% | — | — | |
| Q1 2009 | +1.8% | — | — | |
| Q1 2010 | +1.6% | — | — | |
| Q4 2009 | -0.4% | — | — | |
| Q2 2008 | -1.6% | — | — | |
| Q3 2009 | -1.6% | — | — | |
| Q3 2008 | -1.6% | — | — | |
| Q4 2008 | -1.4% | — | — | |
| Q2 2009 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro